EFFICACY AND SAFETY OF DAPAGLIFLOZIN ON STANDARDIZED CGM METRICS IN PATIENTS WITH TYPE 1 DIABETES


Por: Leon, J, Izquierdo, E, Sierra, N, Exposito, J, Morant, C, Torres, S, Pardo, I and Arino, C
Publicada: 1 jun 2021
Resumen:

Filiaciones:
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

 Univ Valencia, Dept Med, Valencia, Spain

 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain
:
 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain
:
 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain
:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

 Univ Valencia, Dept Med, Valencia, Spain

 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain
ISSN: 15209156





DIABETES TECHNOLOGY & THERAPEUTICS
Editorial
Mary Ann Liebert Inc., 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 23 Número:
Páginas: 54-54
WOS Id: 000656638700143

MÉTRICAS